Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics is a clinical-stage biotech with a strong cash runway but deeply negative operating economics. The SEC 10-Q filed 2026-08-06 reports $910.93M of cash and marketable securities at 2026-06-30, net operating cash outflow of $105.22M for the first six months of 2026, and a stated runway into 2029, with no material interest-bearing debt disclosed. Against that, revenue remains small ($15.36M in FY2025) and losses/cash burn are large (FY2025 net loss $276.48M; trailing free cash flow about -$212.21M), making traditional valuation ratios unreliable and producing negative DCF outputs. Upside relies mainly on clinical/regulatory catalysts and comes with dilution risk, reinforced by an expanded ~$462.98M ATM equity program.

Catalyst map is genuinely two-sided within the window — a soft Q2 print (2026-08-06) and a forward SoftBank Vision Fund 6M-share block sale (2026-08-28) against in-window sell-side PT raises (Citizens; JPMorgan to $31), fresh 13G accumulation (FMR 9.4%, Perceptive 6.4%, Commodore 5.5%) and the ongoing zovegalisib accelerated-approval process (confidence: announced). Media sentiment delta is determinate but flat in positive territory (+0.27 → +0.20), retail is indeterminate, and the legal screen shows no regulator-confirmed activity; moderate red-flag cap applied (conflicting catalyst signals).

RLAY trades 18.19, below its SMA20 (19.00), SMA50 (19.28), EMA9 (18.81) and EMA21 (19.00) but 34% above a rising SMA200 (13.54): a five-week corrective pullback (high 21.27 on 08-19) within a much larger uptrend, now testing the triple-touched support shelf 18.03-18.10 (lows 08-31, 09-10, 09-21) with Williams %R deeply oversold at -86.71. Short-term momentum is still bearish: MACD -0.17 below signal -0.11 below zero with the histogram widening to -0.06, RSI 39.70 falling from 46.56, ADX 15.46 trendless, and price printing lower highs (19.69 -> 19.40 -> 19.17) plus a lower low (18.05) today on a -3.45% close. A pullback/oversold limit into the support shelf is a countertrend bid (price < SMA50 with MACD < 0) and is blocked by the trend-alignment gate; the breakout/momentum-stop alternative has no momentum confirmation (negative and widening MACD, weak ADX, price below SMA20/50), so no tradable setup is actionable. Do Nothing.